Loading...
Loading...
VIVUS
VVUS is trading significantly lower today. At last check, shares of VVUS were trading at $7.51, down over 15% from Monday's close.
Orexigen Therapeutics'
OREX rejection letter from the FDA for its diet drug Contrave may be responsible for today's pessimism.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: Intraday UpdateMovers
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in